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Abstract
Objective: Previous studies have demonstrated a cross-sectional relationship between antiretroviral adherence and HIV
virological suppression. We assessed the predictive value of baseline adherence in determining long-term virological failure.
Design: We assessed baseline adherence via an adherence questionnaire between administered to all consenting patients
attending antiretroviral clinics in Khayelitsha township, South Africa, between May 2002 and March 2004. Virological status
was ascertained after five years of follow up and multivariate analysis used to model associations of baseline variables and
medication adherence with time to viral suppression or failure.
Results: Our adherence cohort comprised 207 patients, among whom 72% were female. Median age was 30 years and
median CD4 count at initiation was 55 cells/mm
3. We found no statistically significant differences between baseline
characteristics and early adherence groups. Multivariate analysis adjusting for baseline CD4 and age found that patients
with suboptimal baseline adherence had a hazard ratio of 2.82 (95% CI 1.19–6.66, p=0.018) for progression to virological
failure compared to those whose baseline adherence was considered optimal.
Conclusions: Our longitudinal study provides further confirmation of adherence as a primary determinant of subsequent
confirmed virological failure, and serves as a reminder of the importance of initial early investments in adherence counseling
and support as an effective way to maximize long-term treatment success.
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Introduction
The widespread availability of antiretroviral therapy (ART) has
changed the course of HIV infection in developed countries, and
comparable benefits are observed in resource-limited settings. The
provision of effective ART is increasingly understood to be critical
for both medical and a public health reasons. Maintaining
virological suppression is an important objective for both the
individual (reduced morbidity and mortality) and at the population
level (reduced resistance [1] and transmission [2]).
A mixture of biologic factors such as virus type, host
immunology, disease status and genetics, together with character-
istics of medications such as drug potency, toxicity, formulation,
and pharmacology can influence adherence and therapeutic
success. Thus, virological failure may result from suboptimal
adherence, poor drug potency, drug resistance, or a combination
of these factors [3].
Amid these multiple explanations, sub-optimal adherence to
medication has been recognized as one of the main patient-mediated
risk factors for treatment failure [3] and several studies have
demonstrated a cross-sectional relationship between adherence and
virological suppression [4–7]. It is unknown whether patient-
mediated factors may predict poor adherence, and thus poor
virological suppression, in the long-term. We aimed to assess this
relationship in a longtitudinal study to determine the predictive value
of baseline adherence in determining virological failure over time.
Methods
Study Setting and data sources
Our study includes patients enrolled in an HIV treatment
programme, in Khayelitsha township, South Africa. ART was first
provided through a pilot demonstration project in May 2001, with
initial capacity to provide ART for 180 adults. By the end of 2007,
the service had cumulatively enrolled over 7000 adults onto ART
as part of the routine programme [8].
We used data derived from a baseline adherence questionnaire
done in Khayelitshsa township during the early phase of
antiretroviral provision in 2002. This adherence study was
conducted at a time when the ability of people in Africa to
adhere to antiretroviral medication was questioned, a hypothesis
that has since been found to be unsupported by evidence [9].
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onto antiretroviral therapy at primary care clinics in Khayelitshsa
township, South Africa between May 2002 and March 2004. Self-
reported adherence was assessed by a dedicated study team
unrelated to the provision of clinical care using a modified version
of the AIDS Clinical Trials Group questionnaire [10] that was
forward- and back-translated and piloted prior to administration.
We assessed adherence one and three months after initiation of
ART and considered patients as highly adherent if they reported
$95% adherence to medication; otherwise, adherence was
considered as suboptimal.
Baseline and outcome data were collected as standard indicators
for monitoring and evaluation in the Khayelitsha programme. Viral
load (NucliSens EasyQ HIV-1 assay (bioMerieux, Boxtel, The
Netherlands) and CD4 count (single-platform panleucogating
method) were assessed at baseline and every six months according
to manufacturer’s instructions. Virological failure was defined as two
consecutive HIV RNA levels greater than 5000 copies/ml, in
accordance with national guidelines. Mortality ascertainment is
corrected through linkages with the South African vital registration
system [8]. The duration of follow-up for this study was five years.
Statistical analyses
Descriptive analyses were based on percentages and frequencies
for categorical variables and medians and interquartile ranges
(IQR) for continuous variables. Continuous variables were
assessed for skew and as all demonstrated non-normality they
were compared using the Wilcoxon rank-sum test. Proportions
were compared using the x
2test and, in the case of small numbers,
the Fisher’s Exact test. We used Nelson-Aalen cumulative hazards
estimates to describe time to confirmed virological failure per
adherence group, as this method provides a appropriate summary
for failure events [11]. Univariate cox regression was used to
model the individual associations of baseline variables and
medication adherence with time to viral suppression or failure;
variables were stratified into discrete categories as follows: early
adherence (,95% or $95%), baseline CD4 (,50 cells/mm
3 or
$50 cells/mm
3), sex (male or female), HAART regimen
(efavirenz- or nevirapine-based), and age (per 10 years). Multivar-
iate models of associations with virological failure included
variables associated with poor adherence in univariate analysis
adjusted for potential confounders identified a priori. Hazard
proportionality was assessed by analysis of scaled Schoenfeld
residuals. All reported p values are exact and 2-tailed, and for each
analysis p,0.05 was considered significant. All analyses were
performed using STATA version 11.0 (StataCorp, College
Station, Texas).
All aspects of data collection (adherence questionnaire, analysis
of routine cohort data and the linkage to the national death
registry) were approved by the University of Cape Town Research
Ethics Committee. As the data is based out routinely collected data
and anonymized, informed consent was not sought.
Results
Our adherence cohort comprised 207 patients, among whom
149 (72%) were female. The median age at ART initiation was 30
years (IQR 28–37) years and the majority (80%) received an
efavirenz-based regimen. Median CD4 count at initiation was 55
cells/mm
3 (IQR 20–115 cells/mm
3) and median HIV-1 RNA
levels at initiation was 5.03 log10 copies/mL (IQR 4.3–5.5 log10
copies/mL). Our early adherence assessment found that 181 (87%)
patients were considered highly adherent. We found no statistically
significant differences between baseline characteristics and early
adherence groups (Table 1).
In our univariate analysis suboptimal early adherence was the
only association with virological failure (hazard ratio 2.72, 95%CI
1.16–6.31, p=0.02) (Table 2). In multivariate analysis we adjusted
for baseline CD4 and age as these have been found to be
associated with virological failure in larger studies from the same
population [8]; this analysis found that patients with suboptimal
baseline adherence had a hazard ratio of 2.82 for progression to
virological failure compared to those whose baseline adherence
was considered optimal (95% CI 1.19–6.66, p=0.018). Cumula-
tive hazard estimates by adherence category are described in
Figure 1.
Discussion
Our longitudinal study provides further confirmation of
adherence as a primary determinant of subsequent confirmed
virological failure, reinforcing the findings of previous studies that
associate adherence with viraemia at a single point in time
concurrent to or soon after the adherence measures [12].
We found that early adherence was a more important predictor
of long-term virological suppression than prognostic variables such
Table 1. Patient characteristics.
Category Subcategory
Total patients
(n=207)
Patients with
adherence $95% (n=181)
Patients with
adherence ,95% (n=26) p
Sex, n (%) Male 58 (28) 50 (28) 8 (31) 0.74
Female 149 (72) 131 (72) 18 (69)
Age, median (IQR) 30 (28–37) 31 (8–37) 30 (26–32) 0.147
Baseline CD4, median (IQR) 55 (20–115) 51 (19–121) 59.5(23–102) 0.71
Baseline VL, median (IQR) 110,000 (21,000–310,000 110,000 (20,000–320-000) 155,550 (97,000–300,000) 0.19
Regimen, n (%) EFV 165 (80) 144 (79) 21 (81) 0.24*
NVP 40 (19) 36 (20) 4 (15)
Other 1 (1) 1 (1) 1 (4)
Prior TB Yes 98 (47) 87 (48) 11 (42) 0.58
No 109 (53) 94 (52) 15 (58)
*Fishers exact; EFV, efavirenz; NVP, nevirapine; TB, tuberculosis; VL, viral load; IQR, interquartile range.
doi:10.1371/journal.pone.0010460.t001
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better-resourced settings [13]. Patients initiating ART and
surviving the first three months of therapy typically have improved
survival outcomes in the long term if they can maintain optimal
adherence [14].
The use of routine viral load monitoring in South Africa enables
the exploration of associations with confirmed virological failure.
The confirmation of failure, subsequent to a period of adherence
optimization, has been shown to identify patients with a high
probability of multi-class drug resistance [15].
Our study was not able to distinguish whether the association
between virological failure and early adherence was due to the
early adherence being a marker of long term sup-optimal
adherence, or due to ongoing viral replication under selective
Table 2. Associations between baseline characteristics and time to virological failure.
Predictor variable Category Failures n, % Univariate Multivariate
HR (95%CI) p HR (95%CI) p
Adherence .95% 25 (78.1%) 1 1
,95% 7 (21.9%) 2.72 (1.17–6.31) 0.020 2.82 (1.19–6.66) 0.018
Sex Male 12 (27.5%) 1
Female 20 (62.5%) 0.98 (0.93–1.03)* 0.12
Age 20–29 15 (46.9%) 0.98 (0.93–1.03)* 0.35 0.98 (0.93–1.02) 0.43
30–39 13 (40.6%)
40–49 2 (6.3%)
50–59 2 (6.3%)
Baseline CD4 #0.5610
9 cells/L 17 (53.1%) 1 1
.0.5610
9 cells/L 15 (46.9%) 0.79 (0.39–1.60) 0.52 0.69 (0.34–1.43) 0.32
Regimen NVP 6 (18.7%) 1
EFV 26 (81.3%) 1.08 (0.44–2.94) 0.87
*per category; EFV, efavirenz; NVP, nevirapine.
schoenfelds p=0.12.
doi:10.1371/journal.pone.0010460.t002
Figure 1. Cumulative hazard estimate for virological failure.
doi:10.1371/journal.pone.0010460.g001
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association we describe validates the structured adherence
interventions that are commonplace in the public health approach
to ART, including facility-based counseling [16], and the use of
early viral load testing to identify patients who might benefit from
further adherence-promoting interventions [17].
Several issues need to be considered with respect to the external
validity of our findings. First, there is no agreed definition of what
constitutes sub-optimal adherence. We applied a conservative cut-
off of 95% partly because the drug regimes used did not include
boosted protease inhibitors, and partly because of the expectation
of poor adherence. Nevertheless, the fact that the majority of our
cohort (87%) was considered to be highly adherent is consistent
with other findings that display, on average, good adherence
within large patient populations [18]. Second, the use of self-
reports in assessing medication adherence is subject to information
(recall) bias. There is no gold standard for medication adherence,
but studies from similar settings in southern Africa have found that
self-report can provide a reliable measure compared to other
methods [19], especially when administered by independent
researchers rather than members of the clinical team. Finally,
our adherence cohort was established during the early phase of the
programme when most patients were severely immuno-compro-
mized at the start of ART, as indicated by low median baseline
CD4. In general baseline CD4 at ART initiation is today much
higher than in previous years, both in this cohort [8] and other
cohorts [20]. Low baseline CD4 has been found to be associated
with virological failure [21], although the extent to which this
relates to poor adherence is not known. The patients we describe
had to take treatment at least twice daily, at least two different
tablets, and often with uneven dosing. They were at relatively high
risk of haematological and hypersensitivity reactions [22]. While
great strides have been made in improving access to treatments in
South Africa, we remain far from providing optimal treatments for
patients from an adherence perspective.
As ART programmes mature and lessons emerge over time,
concern is growing around the challenges of sustaining long-term
adherence [23]. Our study serves as a reminder that a patients’
initial experience with antiretroviral medication is critically
important. Thus while models of care need to be developed to
support ART care over time, the initial early investments in
adherence counseling and support is an effective way to maximize
the likelihood of treatment success in the longer term.
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